#USA #New York #Rosen Law Firm #Securities Class Action #MoonLake Immunotherapeutics

Rosen Law Firm Investigates MoonLake Immunotherapeutics

The Rosen Law Firm, a distinguished global entity specializing in investor rights, has announced an investigation into potential securities class action claims concerning MoonLake Immunotherapeutics (NASDAQ: MLTX). This inquiry comes in the wake of substantial concerns regarding misleading public statements made by the company that may have adversely affected its investors.

Background of the Investigation

On September 29, 2025, MoonLake released a current report via Form 8-K to the SEC, revealing critical updates about their VELA-2 trial. The report disclosed that unforeseen events within the placebo group hindered the trial from meeting its primary endpoint goals statistically. As a result of this unsettling announcement, MoonLake faced a dramatic plunge in stock value, down 89.9% on the same day. This drastic decline has prompted the Rosen Law Firm to investigate whether MoonLake's shareholders have actionable claims against the company for potentially misleading information.

The Legal Framework

Investors who purchased securities from MoonLake may be entitled to compensation through a contingency fee arrangement, meaning they won't bear any upfront costs. The Rosen Law Firm is preparing a class action lawsuit with the goal of recovering losses sustained by affected shareholders. Potential plaintiffs are encouraged to join the emerging class action to strengthen their claims.

To pursue participation in this class action, investors can visit Rosen Law Firm's website or contact attorney Phillip Kim at 866-767-3653. The firm emphasizes the importance of selecting seasoned counsel, as many firms that publicize such litigation may lack the necessary resources or experience.

Why Choose Rosen Law Firm?

Rosen Law Firm has established a remarkable track record in securities class actions, boasting the largest settlement against a Chinese company to date. It consistently ranks among the top leaders in the industry, having recovered hundreds of millions of dollars for investors over the years. In 2019 alone, the firm achieved over $438 million in recoveries for its clientele. Furthermore, the firm's founding partner, Laurence Rosen, has garnered recognition in the legal community, including being named a Titan of the Plaintiffs’ Bar by Law360.

Rosen Law Firm stands out in the legal landscape not only for its successful outcomes but also for a dedicated approach to shareholder advocacy. Many of its attorneys have received accolades from respected legal entities, reinforcing the firm’s credentials in this complex field of law.

Ongoing Developments

The firm's commitment to its clients is evident through continuous updates shared on its social media platforms. Investors are encouraged to follow the Rosen Law Firm on LinkedIn, Twitter, and Facebook for the latest information regarding legal developments and investor news.

Conclusion

In light of the recent events surrounding MoonLake Immunotherapeutics, Rosen Law Firm's inquiry represents a critical component of holding companies accountable for their communications and actions. Shareholders are urged to stay informed and take action to protect their investments. For further details, reach out to the Rosen Law Firm directly or visit their website for more information.

Contact Information
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll-Free: (866) 767-3653
Email: [email protected]
www.rosenlegal.com